Introduction {#s1}
============

Metastatic colonization is a highly inefficient process that only a small subset of disseminated tumor cells accomplish ([@bib11]). A growing body of literature suggests that cancer stem cells (CSC), tumor cells with the ability to self-renew and differentiate, play important roles not only in metastatic colonization but also in establishing the metastatic niche to support metastatic colonization ([@bib14]). Using the MMTV-PyMT mouse breast cancer model, which spontaneously metastasizes to the lungs, Malanchi and colleagues reported that only the CSC population, identified as CD24^+^ CD90^+^, were capable of initiating lung metastases and secondary metastases ([@bib6]; [@bib9]; [@bib10]). Additionally, only a subset of the injected CSC population resulted in metastatic nodules. Periostin (POSTN) was identified by microarray RNA profiling studies as a stromal factor involved in maintaining the normal stem cell niche and demonstrated to be secreted by stromal fibroblasts, but not by infiltrating tumor cells ([@bib10]). POSTN is a secreted protein that is incorporated in the extracellular matrix and has been associated with metastasis in several human cancers ([@bib3]). The functional necessity of POSTN was investigated by observing the pulmonary metastatic potential in POSTN-knockout MMTV-PyMT mice, which showed a statistically significant decrease compared to controls ([@bib10]). This was further demonstrated by observing a rescue in metastatic efficiency by injecting POSTN-deficient tumor cells into wild-type recipient mice ([@bib10]). Investigating the mechanism of POSTN-induced metastasis, Malanchi and colleagues reported a decrease in colony formation in vitro with POSTN-deficient tumor cells or wild-type CSCs co-cultured with POSTN-deficient stromal cells, demonstrating the involvement of POSTN in stem cell maintenance ([@bib10]). Furthermore, POSTN was reported to bind to Wnt ligands, leading to an increase in Wnt signaling in CSCs, a known regulator of stem cell maintenance in a variety of tissues ([@bib10]). Taken together, these results suggest that CSCs are essential for metastatic colonization and that CSCs induce stromal fibroblasts to secrete POSTN in the metastatic niche to support tumor cell outgrowth by augmenting the Wnt signaling pathway.

Malanchi and colleagues\' findings suggest that targeting of POSTN in the metastatic niche could potentially be used to treat metastasis. The key experiments included for replication were selected because they examine the induction of *POSTN* expression in the pulmonary stromal fibroblasts and test the role of POSTN in primary tumor formation and metastatic efficiency, which are relevant as the role of POSTN as a possible prognostic marker and target for anticancer therapies is explored ([@bib16]; [@bib12]). Indeed, treatment of mice with POSTN specific DNA aptamers, single-stranded DNA oligonucleotides designed to bind and inhibit POSTN, was shown to decrease primary tumor growth and metastasis in a xenograft model of mammary tumorigenesis ([@bib8]). Additionally, treatment of ovarian xenograft models with a neutralizing antibody to POSTN resulted in a reduction of metastatic potential and tumor growth, migration, and invasion ([@bib17]).

Figures 3A, 3B, and Supplemental Figure S13 examine the role of POSTN in primary tumor formation and metastasis utilizing a MMTV-PyMT mouse model of mammary tumor formation. This mouse model develops primary mammary tumors that spontaneously metastasize to the lung ([@bib6]; [@bib9]). *MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ mice and their *Postn*^*+/+*^ counterparts were analyzed for primary tumor formation and metastasis. Primary tumor size was measured by weight, and the number of metastases was determined by counting lung metastatic lesions. Malanchi and colleagues reported in Figures 3A and S13A that POSTN does not affect the size of the primary tumors, but *MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ mice develop significantly fewer metastases than their *Postn*^*+/+*^ counterparts ([@bib10]). The importance of stromal POSTN was also demonstrated in another study in which orthotopic inoculation of gastric cancer cells into *Rag2*^*−/−*^*; Postn*^*−/−*^ mice reduced tumor size, decreased invasiveness, and decreased growth compared to *Rag2*^*−/−*^; *Postn*^*+/+*^ mice ([@bib7]). Additionally, overexpression of POSTN in human mammary epithelial and breast cancer cells resulted in enhanced tumor growth and metastasis ([@bib15]), which is similar to a colon cancer cell model where overexpression of POSTN resulted in an increase in the number and size of liver metastases ([@bib2]). The experiment reported in Figures 3A, 3B, and Supplemental Figure S13 will be replicated in Protocol 1.

Malanchi and colleagues show that POSTN is expressed primarily in fibroblasts and to a lesser extent in endothelial cells but is not expressed in immune cells at sites of metastasis ([@bib10]). This was determined by FACS sorting cells from lungs with macrometastases to isolate CD34^+^/CD31^−^ pulmonary fibroblasts, CD31^+^ endothelial cells, and CD45^+^ immune cells. Quantitative PCR of messenger RNA extracted from each of these cell populations was then used to determine the relative expression of *POSTN* in each cell type as reported in Figure 2H ([@bib10]). RNA in situ hybridization and immunostaining showed similar results ([@bib10]). Similarly, another study used immunohistochemistry and immunofluorescence to show that POSTN was localized to stromal fibroblasts in human samples of advanced gastric cancer ([@bib7]). Yet, another study utilized tandem mass spectrometry and immunofluorescence to find POSTN concentrated in the extracellular matrix surrounding sites of neovascularization of micrometastases and within the tips of endothelial cells involved in the neovascularization ([@bib5]). The experiment reported in Figure 2H will be replicated in Protocol 2.

Materials and methods {#s2}
=====================

Protocol 1: tumor size and metastases of *MMTV-PyMT*^*+/tg*^; *Postn*^*+/+*^ and *MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ mice {#s2-1}
-------------------------------------------------------------------------------------------------------------------------

This experiment examines the requirement of POSTN in metastatic colonization using the MMTV-PyMT mouse model. Female mice carrying the MMTV-PyMT transgene that are either *Postn*^+/+^ or *Postn*^*−/−*^ will be examined for changes in primary tumor size and the number of spontaneously formed pulmonary macrometastases, which is a replication of the experiment reported in Figures 3A, 3B, and Supplemental Figure 13. This experiment will also generate lung tissue from *MMTV-PyMT*^*+/tg*^; *Postn*^+/+^ female mice that are positive with metastatic disease for use in Protocol 2.

### Sampling {#s2-1-1}

■ Experiment has 2 cohorts:◯ Cohort 1: *MMTV-PyMT*^*+/tg*^; *Postn*^+/+^ female mice.◯ Cohort 2: *MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ female mice.■ Experiment will use the following number of mice per cohort:◯ Cohort 1: 14 mice.◯ Cohort 2: 15 mice.Note: Derive mice from consecutive litters and analyze development of tumors and metastases until the two cohorts reach the indicated numbers.■ To account for outlier data, as presented in the original publication, 5% and 10% more mice were added to each cohort, respectively, to ensure at least 13 mice survive each cohort for a minimum power of 80%.◯ See 'Power calculations' section for details.

### Materials and reagents {#s2-1-2}

ReagentTypeManufacturerCatalog \#Comments*MMTV-PyMT*^*+/tg*^; *Postn*^+/−^ FVB male mouseAnimal modelOriginal labn/aFrom original lab*MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ FVB male mouseAnimal modelOriginal labn/aFrom original lab*Postn*^*−/−*^ FVB female miceAnimal modelOriginal labn/aFrom original lab*Postn*^+/+^ FVB female miceAnimal modelCharles RiverStrain code: 207Original was from FrancePureGenome tissue DNA extraction kitKitEMD Millipore72635Original not specifiedMMTV-PYVT384 primerNucleic acidSequences provided by original authors; specific brand information will be left up to the discretion of the replicating lab and recorded laterMMTV-PYVT385 primerNucleic acidPostn-5′ primerNucleic acidPostn-3′ primerNucleic acidINT-as primerNucleic aciddNTPs (10 mM)ChemicalSigma--AldrichD7295Included during communication with authors. Original brand not specifiedTaq-polymerase (with tubes of 10× PCR buffer and 25 mM MgCl~2~)EnzymeSigma--AldrichD4545Included during communication with authors. Original brand not specifiedPCR systemEquipmentApplied Biosystems StepOneOriginal not specifiedIsofluraneChemicalSpecific brand information will be left up to the discretion of the replicating lab and recorded laterStereoZoom stereomicroscope, zoom range 0.8×--4.0×InstrumentBausch & Lombn/aOriginal a Leica M205 FA

### Procedure {#s2-1-3}

Breed *MMTV-PyMT*^*+/t*g^*; Postn*^+/−^ or *MMTV-PyMT*^*+/tg*^*; Postn*^*−/−*^ male mice with *Postn*^+/+^ and *Postn*^*−/−*^ female mice to obtain *MMTV-PyMT*^*+/tg*^; *Postn*^+/+^ control and *MMTV-PyMT*^*+/tg*^*; Postn*^*−/−*^ experimental female mice, respectively.a. Do not use *MMTV-PyMT* female mice for breeding as they develop mammary tumors. Additionally, *MMTV-PyMT*^*+/tg*^ males cannot be crossed with *MMTV-PyMT*^*+/tg*^ females as the progeny will have a double dose of the oncogene and develop extremely aggressive tumors that cannot be used in this study.b. For generation of the *MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ experimental female mice, male *MMTV-PyMT*^*+/tg*^; *Postn*^*−/−*^ male mice will be crossed with *Postn*^*−/−*^ female mice.c. For generation of the *MMTV-PyMT*^*+/tg*^; *Postn*^+/+^ control female mice, the *MMTV-PyMT*^*+/tg*^; *Postn*^+/−^ male mouse will be crossed to *Postn*^+/+^ female mice to obtain *MMTV-PyMT*^*+/tg*^; *Postn*^+/+^ male mice that will then be crossed with *Postn*^+/+^ female mice.d. As mice obtained were found to contain agents, cross-foster rederivation of mice will be performed based on the following procedure ([@bib1]). Donor dam will be placed with male mice 5 days a week Monday afternoon to Friday morning and plugs will be checked daily. When dam is found plugged, she should be single housed and date of plug will be recorded as a sign of pregnancy. Once the pregnancy is confirmed, a timed pregnant mouse will be ordered to use as a foster recipient. Foster recipients will ideally have a different fur coat color than the donor dam, so the identification of the fostered pups will be easier. Consequently, the donor and recipient dams will be removed from their cages and placed in separate clean cages. The litter to be fostered will gently be picked up and cleaned with alcohol and passed to a clean tech to be mixed with dirty bedding, nestlet, and other pups from the recipient dam\'s cage. When mixing the pups, they will be gently arranged in the palm of the hand, in contact with nestlet and bedding from the recipient dam\'s cage to transfer the recipient dam\'s scent. All pups will be placed back in the nest and the recipient dam will be returned to the cage. The cage will be monitored visually every 15 min for the first hour; if there is evidence of rejection by the dam (agitation, carrying the pups around), the pups will be removed from the cage and humanely euthanized. The cages will be visually assessed at least twice daily and will not be disturbed for the first 72 hr after fostering in order to avoid any potential cannibalism. All experimental animals will not be treated with Ivermectin or Fenbendazole, as these could change a number of immune parameters affecting tumor growth and take rate.Extract genomic DNA from mouse tail snips using DNA extraction kit following manufacturer instructions.a. From manufacturer\'s instructions follow 'Solid Tissue' assay protocol.Genotype mice by PCR with *MMTV-PyMT* and *Postn* primers.a. MMTV-PYVT384 primer: GGA AGC AAG TAC TTC ACA ACG G.i. This primer is one nucleotide different than what is listed on the Jackson Laboratory [information](http://jaxmice.jax.org/protocolsdb/f?p=116:2:0::NO:2:P2_MASTER_PROTOCOL_ID,P2_JRS_CODE:14626,002374) for stock number 002374 (FVB/N-Tg(MMTV-PyVT)634Mul/J), but is used successfully by the original lab.b. MMTV-PYVT385 primer: GGA AAG TCA CTA GGA GCA GGG.c. Postn-5′ primer: GGT GCT TCT GTA AGG CCA TC.d. Postn-3′ primer: GTG AGC CAG GAC CTT GTC ATA.e. INT-as primer: AGC ACT GAC TGC GTT AGC AA.f. Genotyping will be determined by examining both amplicon size and presence.i. MMTV-PyMT conditions (oncogene = 556 bp band):10× PCR buffer1.50 µl50 mM MgCl~2~0.45 µl10 mM dNTPs0.30 µlMMTV-PYVT384 primer0.10 µlMMTV-PYVT385 primer0.10 µlTaq-polymerase0.20 µlH~2~OBring up to 13 µlDNA (1:20 dilution)2 µlCycling parameters:94°C pause.94°C for 3 min.12 cycles of:i. 96°C for 20 s.ii. 64°C for 30 s.iii. 72°C for 65 s.25 cycles of:i. 94°C for 20 s.ii. 58°C for 30 s.iii. 72°C for 35 s.72°C for 2 min.20°C pause.ii. *Postn* conditions (WT = 245 bp band; KO = 182 bp band):10× PCR buffer1.50 µl50 mM MgCl~2~0.45 µl10 mM dNTPs0.30 µlPostn-5′ primer0.10 µlPostn-3′ primer0.10 µlINT-as primer0.10 µlTaq-polymerase0.20 µlH~2~OBring up to 13 µlDNA (1:20 dilution)2 µlCycling parameters:94°C pause.94°C for 1 min.45 cycles of:i. 96°C for 6 s.ii. 59°C for 20 s.iii. 72°C for 30 s.20°C pause.Separate and image amplicons by agarose gel electrophoresis.Monitor *MMTV-PyMT*^+/tg^*; Postn*^*+/+*^ and *MMTV-PyMT*^*+/tg*^*; Postn*^*−/−*^ female mice for tumor development and keep until tumor disease is fully developed and the metastatic disease is estimated to occur.a. Record age of mice when palpable tumors are detected.i. Multiple tumors will form and grow until they reach a significant size.b. Monitor health status of mice. If mice have to be euthanized prior to reaching fully developed primary tumors exclude mice from study and record reason for euthanasia.c. Tumor disease is fully developed when primary tumors have developed in all mammary glands with an average weight around 1 g per tumor.i. Both cohorts of mice will develop tumors approximately within 3--4 months of age and up to 6 months.ii. Record mice with tumors that are large and form close to the neck as these may give metastasis more efficiently.d. Record age of mice when sacrificed and determine time gap between detection and fully developed tumor.i. Method of euthanasia is isoflurane overexposure (2--5% at 1 l/min) followed by cervical dislocation.Dissect primary tumor and lung tissue from mice.a. Weigh primary tumors.i. Record total weight of all primary tumors together for each mouse.ii. Record the number of primary tumors for each mouse.iii. Divide total weight of all primary tumors by number of primary tumors to obtain a reference primary tumor weight for each mouse.Dissect lungs and blindly count the number of macrometastatic nodules on every side of all separated lobes of the lung using a stereomicroscope.a. Do not fix or stain tissues.b. Quickly count large macrometastatic nodules (≥1 mm in diameter) on all sides.Immediately after counting macrometastasis, use the first six lungs identified from *MMTV-PyMT*^*+/tg*^;*Postn*^*+/+*^ female mice that are positive with metastatic disease for further analysis (Protocol 2).a. Should be approximately 5--6 months of age.i. Exclude lungs from mice that are euthanized before this age.b. Use mice with detectable metastatic disease and record number of macrometastases in each lung used and the total weight of the primary mammary tumors.

#### Deliverables {#s2-1-3-1}

■ Data to be collected:◯ Mouse health records (age of palatable tumor detection, reason for early euthanasia and exclusion of mice, age of mice with fully developed tumor when sacrificed, mice with large tumors formed close to the neck).◯ Gel images of PCR genotyping (Compare to Figure S10).◯ Number of primary tumors formed and total weight of all tumors for each mouse.◯ Raw numbers and box and whisker plot of weight of primary tumors (total weight divided by number of primary tumors) for each mouse. (Compare to Figure 3A and S13).◯ Raw numbers of pulmonary macrometastases for each mouse (Compare to Figure 3B and S13).◯ Box and whisker plot of number of pulmonary macrometastases for each mouse. (Compare to Figure 3B and S13).■ Sample delivered for further analysis:◯ Lungs for FACS and qRT-PCR analysis for Protocol 2.

### Confirmatory analysis plan {#s2-1-4}

The original paper reported outliers in each cohort of mice. As these appear to have not been included in the original analysis, we will also remove any outliers from the analysis for comparison. But the analysis will also be performed with all data values. Outliers are determined as 1.5 times the interquartile range.

This replication attempt will perform the following statistical analysis listed below:■ Statistical analysis:◯ Primary tumor weight in *MMTV-PyMT*^*+/tg*^;*Postn*^*+/+*^ mice relative to *MMTV-PyMT*^*+/tg*^*;Postn*^*−/−*^ mice.Unpaired two-tailed *t*-test.◯ Number of pulmonary macrometastases in *MMTV-PyMT*^*+/tg*^*;Postn*^*+/+*^ mice relative to *MMTV-PyMT*^*+/tg*^*;Postn*^*−/−*^ mice.Unpaired two-tailed *t*-test.◯ The replication attempt will also perform negative binomial regression analysis of the macrometastases count data.■ Meta-analysis of effect sizes:◯ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper, and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-1-5}

The mice in the original study were from an 8^th^ generation backcross to the FVB line, thus it was on a mixed background, while the mice used in the replication will be from a pure 10th generation backcross to the FVB line. This may make a difference in the effect size and will be included in the discussion of the results of the replication. Additionally, mice will undergo cross-foster rederivation to attempt to remove agents currently associated with the mice. All known differences of materials and reagents are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-1-6}

Mice will undergo cross-foster rederivation to attempt to remove agents currently associated with the mice that could alter immune parameters affecting tumor growth and take rate. All data obtained from the experiment---raw data, data analysis, control data, and quality control data---will be made publicly available, either in the published manuscript or as an open access data set available on the Open Science Framework project page for this study (<https://osf.io/vseix>).

Protocol 2: POSTN expression in lung stroma with macrometastases {#s2-2}
----------------------------------------------------------------

This experiment uses quantitative PCR to detect the expression level of *POSTN* in CD34^+^/CD31^−^ pulmonary fibroblasts, CD31^+^ endothelial cells, and CD45^+^ immune cells isolated from lungs of mice with macrometastases, which is a replication of the experiment reported in Figure 2H.

### Sampling {#s2-2-1}

■ Experiment will use six lungs for a minimum power of 82%.◯ See appendix for detailed power calculations.■ Each lung will be isolated into 3 cohorts:◯ Cohort 1: CD34^+^/CD31^−^ pulmonary fibroblasts from *MMTV-PyMT*^*+/tg*^;*Postn*^*+/+*^ mice.◯ Cohort 2: CD31^+^ endothelial cells from *MMTV-PyMT*^*+/tg*^;*Postn*^*+/+*^ mice.◯ Cohort 3: CD45^+^ immune cells from *MMTV-PyMT*^*+/tg*^;*Postn*^*+/+*^ mice.Each cohort will be sorted using the following antibodies:◯ CD45.◯ CD31.◯ CD34.◯ Isotype controls.◯ Unstained control.■ Each cohort will be analyzed for the following gene expression levels:◯ POSTN.◯ GAPDH.

### Materials and reagents {#s2-2-2}

ReagentTypeManufacturerCatalog \#Comments50 ml tubesLabwareSigma--AldrichCLS430290Originally not specifiedHank\'s balanced salt solution (HBSS)BufferSigma--AldrichH6648Included during communication with authors. Original brand not specifiedLiberase TMEnzymeRoche05401127001--Liberase THEnzymeRoche05401151001--DNaseEnzymeSigma--AldrichDN25--Phosphate buffered saline (PBS) without MgCl~2~ and CaCl~2~BufferSigma--AldrichD8537Original brand not specifiedEDTAChemicalIncluded during communication with authors. Specific brand information will be left up to the discretion of the replicating lab and recorded laterBovine serum albumin (BSA)ChemicalSigma--AldrichA3803Included during communication with authors. Original brand not specified100 µm cell strainerLabwareCorning431752Original brand not specified2.5 ml syringeLabwareIncluded during communication with authors. Specific brand information will be left up to the discretion of the replicating lab and recorded laterFetal bovine serum (FBS)Cell cultureSigma--AldrichF0392Original brand not specifiedPolypropylene (opaque) FACS tubesLabwareSpecific brand information will be left up to the discretion of the replicating lab and recorded laterCD45 (clone 30-F11) PE-Cy5.5 antibody (rat IgG2b, kappa)AntibodieseBioscience35-0451-80Use at 1:300CD31 (clone 390) Pac.Blue antibody (rat IgG2a, kappa)AntibodiesInvitrogenRM5228Use at 1:200CD34 (clone RAM34) PE antibody (rat IgG2a, kappa)AntibodiesBD Pharmingen551387Use at 1:50Rat IgG2b, kappa isotype control PE-Cy5.5AntibodieseBioscience35-4031Use at 1:300 dilution. Originally not specifiedRat IgG2a, kappa isotype control Pac.BlueAntibodiesInvitrogenR2a28Use at 1:200 dilution. Originally not specifiedRat IgG2a, kappa isotype control PEAntibodiesBD Pharmingen553930Use at 1:50 dilution. Originally not specified7AADChemicalBioLegend420403Use at 1:1000. Original brand not specifiedFlow cytometric cell sorterInstrumentBD PharmingenFACSAria IIOriginal from Beckman CoulterFlowJoSoftware------TRI reagentChemicalSigma--AldrichT9424Replaces RNA extraction kit from QiagenOligo dT (18)Nucleic acidLife TechnologiesSO132Included during communication with authors. Original brand not specifiedOligo dT (23), AnchoredNucleic acidSigma--AldrichO4387Included during communication with authors. Original was Oligo dT (24). Original brand not specifieddNTPs (10 mM)ChemicalSigma--AldrichD7295Included during communication with authors. Original brand not specified25 mM MgCl~2~ChemicalSigma--AldrichM8787 (part of Sigma--Aldrich D4545 from Protocol 1)Included during communication with authors. Original brand not specifiedSuperscript II (with tube of 5× buffer and 100 mM DTT)EnzymeLife Technologies18064-014Included during communication with authorsRNase inhibitorEnzymeSigma--AldrichR1274Included during communication with authors. Original was RNasinPOSTN 5′ primerNucleic acidSequences provided by original authors; specific brand information will be left up to the discretion of the replicating lab and recorded laterPOSTN 3′ primerNucleic acidGAPDH 5′ primerNucleic acidGAPDH 3′ primerNucleic acidPower SYBR green PCR master mixBufferLife Technologies4368577--Real-time PCR systemEquipmentApplied Biosystems StepOne--Original was from Roche or a StepOnePlus from Applied Biosystems

### Procedure {#s2-2-3}

Note:These metastatic positive lungs from *MMTV-PyMT*^*+/tg*^; *Postn*^*+/+*^ female mice come from Protocol 1.Mince lungs with bended scissors to smooth paste without any clumps and transfer to tube.a. Keep each set of lungs separate (do not pool).Incubate tissue in 6× volume of digestion solution for 1 hr at 37°C with the tube horizontal and shaking at 100 rpm.a. Digestion solution: HBSS supplemented with 0.4 U/ml liberase TM, 0.4 U/ml liberase TH, and 25 µg/ml DNase.i. Liberase TM: stock solution = 26 U/ml = 5 mg/ml; store at −20°C; use at 1:66 dilution.ii. Liberase TH: stock solution = 26 U/ml = 5 mg/ml; store at −20°C; use at 1:66 dilution.iii. DNase: stock solution = 10 mg/ml in PBS; store at −20°C; use at 1:400 dilution.Pellet cells at 180×*g* for 5 min at room temperature.Resuspend cells in cold MACS buffer and filter through 100-µm cell strainer using a rubber tip of 2.5 ml syringe to smash remaining tissue pieces.a. MACS buffer: 2 mM EDTA in PBS supplemented with 0.5% BSA.Wash strainer extensively with MACS buffer to collect all cells and pellet cells at 180×*g* for 5 min.Wash twice in MACS buffer, pelleting cells at 180×*g* for 5 min between washes.Pellet cells at 180×*g* for 5 min, wash once in FACS buffer and pellet cells at 180×*g* for 5 min.a. FACS buffer: 3% FBS in PBS.Resuspend up to 5 × 10^7^ cells total in FACS buffer at 2 × 10^7^ cells/ml in polypropylene (opaque) FACS tubes.Either add antibodies directly, or add antibody dilution mixes, and incubate on ice for 30 min in the dark (if staining high amount of cells put on roller at 4°C).a. CD45-PE·Cy5.5 (use at 1:300 dilution).b. CD31-Pac.Blue (use at 1:200 dilution).c. CD34-PE (use at 1:50 dilution).d. Include an unstained control for gating.e. Include isotype control antibody stains.i. Rat IgG2b, κ---PE-Cy5.5.ii. Rat IgG2a, κ---Pac.Blue.iii. Rat IgG2a, κ---PE.Pellet cells at 180×*g* for 5 min, wash once with 4 ml FACS buffer, and pellet cells at 180×*g* for 5 min (if staining high amount of cells perform another wash).Resuspend cells in 500 µl FACS buffer and filter through filter-membrane into polypropylene (opaque) FACS tubes protected from light.Just before FACS add viability dye.a. 7AAD (use at 1:1000 dilution).Perform FACS analysis on cells.a. Gate for viability (7-AAD^−^), then gate and collect the different populations to be analyzed:i. CD34^+^/CD31^−^ cells.ii. CD31^+^ cells.iii. CD45^+^ cells.iv. Use negative controls (unstained and isotype control antibodies) to determine gating of populations.Isolate RNA from each collected cell population using TRI reagent following manufacturer\'s instructions.a. Quantify RNA concentrations in each sample using a spectrometer.i. Record sample purity (A~260/280~ and A~260/230~ ratios).Reverse transcribe RNA:a. cDNA synthesis:Total RNA1 ng--5 µgoligodT(18)40 pmololigodT(24)40 pmol10 mM dNTPs1.0 µlH~2~OBring up to 12.5 µlb. Heat to 70°C for 5 min, chill on ice for 2 min, then add:5× superscript II buffer4.0 µl100 mM DTT2.0 µlRNasin0.5 µlc. Incubate at 45°C for 2 min, then add:Superscript II1.0 µld. Incubate for 1 hr at 42°C.e. Heat-inactivate at 70°C for 15 min.Prepare samples in technical duplicates with two dilutions of cDNA (1:25 and 1:125) using POSTN and GAPDH primers and the Power SYBR green PCR Master Mix. Use GAPDH as control.a. Primers:i. POSTN 5′ primer: AAT GCT GCC CTG GCT ATA TG.ii. POSTN 3′ primer: GTA TGA CCC TTT TCC TTC AA.iii. GAPDH 5′ primer: CAA GCT CAT TTC CTG GTA TGA CAA T.iv. GAPDH 3′ primer: GTT GGG ATA GGG CCT CTC TTG.b. Set up SYBR mix (contains 1 mM MgCl~2~): 10 µl of 1a into 1b (store on ice in the dark).c. Set up PCR master mix (per reaction):Forward primer1.0 µl of 5 µM (5 pmol/µl)Reverse primer1.0 µl of 5 µM (5 pmol/µl)MgCl~2~0.4 µl (for 2 mM)H~2~OBring up to 4.0 µlSYBR mix1.0 µld. Add 5.0 µl of diluted cDNA and 5.0 µl of PCR master mix to Light cycler capillaries, spin down, and run quantitative PCR reaction following manufacturer\'s instructions.i. Include negative control (no cDNA).e. Analyze and compute ∆∆C~T~ values.

#### Deliverables {#s2-2-3-1}

■ Data to be collected:◯ All FACS plots in gating scheme (including all controls), leading to final population of viable, CD34^+^/CD31^−^, CD31^+^, and CD45^+^ cells.◯ Purity (A~260/280~ and A~260/230~ ratios) and concentration of isolated total RNA from cells.◯ Raw C~T~ qRT-PCR values and ∆∆C~T~ (the C~T~ value of *POSTN* normalized to *GAPDH*).◯ Graph of *POSTN* normalized expression (∆∆C~T~) for each condition. (Compare to Figure 2H).

### Confirmatory analysis plan {#s2-2-4}

This replication attempt will perform the following statistical analysis listed below:■ Statistical analysis:

Note: At the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile (q--q) plot to assess the normality of the data and also perform Levene\'s test to assess homoscedasticity. If the data appear skewed, we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric test.◯ One-way ANOVA of *POSTN* RNA expression in CD34^+^/CD31^−^, CD31^+^, and CD45^+^ cells.◯ Planned comparisons with the Bonferroni correction:CD34^+^/CD31^−^ vs CD45^+^.CD31^+^ vs CD45^+^.■ Meta-analysis of effect sizes:◯ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-2-5}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-2-6}

Negative staining and isotype controls are included to assess antibody staining relative to background during FACS analysis. The sample purity (A~260/280~ and A~260/230~ ratios) of the isolated RNA from each sample will be reported. All data obtained from the experiment---raw data, data analysis, control data, and quality control data---will be made publicly available, either in the published manuscript or as an open access data set available on the Open Science Framework project page for this study (<https://osf.io/vseix>).

Power calculations {#s3}
==================

Protocol 1 {#s3-1}
----------

Summary of original data (estimated from Figure S13).Figure 3B and S13: Number of metastases or size of primary tumorMeanSDNNumber of metastases in MMTV-PyMT; *Postn*^*+/+*^ mice15.7817.5418Number of metastases in MMTV-PyMT:*Postn*^*−/−*^ mice2.7655.06917Size of primary tumor in MMTV-PyMT; *Postn*^*+/+*^ mice1.2210.602318Size of primary tumor in MMTV-PyMT; *Postn*^*−/−*^ mice1.1860.590116

### Size of primary tumor {#s3-1-1}

Test family■ 2-tailed *t*-test, difference between two independent means, alpha error = 0.05.

Sensitivity calculations performed with G\*Power software, version 3.1.7 ([@bib4]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizeMMTV-PyMT; *Postn*^*+/+*^ miceMMTV-PyMT; *Postn*^*−/−*^ mice1.145371[\*](#tblfn1){ref-type="table-fn"}80.0%1313[^1]

### Number of metastases {#s3-1-2}

Test family■ 2-tailed *t*-test, difference between two independent means, alpha error = 0.05.

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib4]).Group 1Group 2Effect size *d*A priori powerGroup 1 sample sizeGroup 2 sample sizeMMTV-PyMT; *Postn*^*+/+*^ miceMMTV-PyMT; *Postn*^*−/−*^ mice1.186517[\*](#tblfn2){ref-type="table-fn"}82.7%1313[^2]

Test family■ Negative binomial regression, alpha error = 0.05.

Analysis of original data: performed with R software, version 3.1.2 ([@bib13]).

Chi-square goodness of fit test, p-value = 0.2535.

Regression coefficient, Genotype (*Postn*^*−/−*^) = −1.742, incident rate ratio = 0.1752, p-value = 0.000923.

Predicted values from model:Data set being analyzedMeanSENumber of metastases in MMTV-PyMT; *Postn*^*+/+*^ mice15.785.594Number of metastases in MMTV-PyMT:*Postn*^*−/−*^ mice2.7651.073

Power Calculations performed with R software, version 3.1.2 ([@bib13]).GroupsNumber of simulationsA priori powerSample sizeNumber of metastases in MMTV-PyMT; *Postn*^*+/+*^ mice and MMTV-PyMT; *Postn*^*−/−*^ mice10,000[\*](#tblfn3){ref-type="table-fn"}81.2%12 per group[^3]

Protocol 2 {#s3-2}
----------

Summary of original data (estimated from Figure 2H).Figure 2H: qPCR analysis of POSTN expressionNMeanSDCD34^+^/CD31^−^ pulmonary fibroblasts31.70.6CD31^+^ endothelial cells30.150.1CD45^+^ immune cells30.010.04

Test family■ ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05.

Power calculations performed with G\*Power software, version 3.1.7 ([@bib4]).

ANOVA F test statistic and partial η^2^ performed with R software, version 3.1.2 ([@bib13]).GroupsF test statisticPartial η^2^Effect size *f*A priori powerTotal sample sizeCD34^+^/CD31^−^, CD31^+^, and CD45^+^F(2,6) = 21.3060.8765742.66496289.8%[\*](#tblfn4){ref-type="table-fn"}6[\*](#tblfn4){ref-type="table-fn"} (3 groups)[^4]

Test family■ 2-tailed *t*-test, difference between two independent means, Fisher\'s LSD test: alpha error = 0.05.

Power calculations performed with G\*Power software, version 3.1.7 ([@bib4]).Group 1Group 2Effect size dA priori powerGroup 1 sample sizeGroup 2 sample sizeCD34^+^/CD31^−^CD45^+^3.97454694.6%[\*](#tblfn5){ref-type="table-fn"}3[\*](#tblfn5){ref-type="table-fn"}3[\*](#tblfn5){ref-type="table-fn"}CD31^+^CD45^+^1.83829081.8%66[^5]
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Registered report: Interactions between cancer stem cells and their niche govern metastatic colonization" for consideration at *eLife*. Your article has been evaluated by Janet Rossant (Senior editor), Gordana Vunjak-Novakovic°(Reviewing editor), and three reviewers, one of whom, M Dawn Teare, has agreed to share her identity.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.°

This Registered report is part of a bigger project named Reproducibility Project: Cancer Biology, which aims to address concerns about reproducibility of scientific data published in the field of cancer research between 2010 and 2012. Within this project, parts of the experiments from 50 selected publications will be reproduced by an independent laboratory.°

The report describes the plan for the reproduction of two selected experiments from the original article "Interactions between cancer stem cells and their niche govern metastatic colonization" by Malanchi et al. in Nature in 2012 ([@bib10]). The first experiment is to measure metastatic lung cancer in MMTV-PyMT transgenic mice crossed with the POSTN Knock out mice, and controls, with focus on the role of periostin in metastatic progression.°

The second experiment is to isolate various cell types from lungs harboring metastasis to confirm the cellular source of periostin in response to metastatic growth. We find the data of high quality and possibly of interest to the scientific community. However, the reviewers also made some comments that we would like you to address.°

1\) The key finding that periostin acts as a fundamental stromal factor for metastatic progression has been meanwhile experimentally validated in several independent labs by using other models. In light of this, it would be helpful to explain in more detail what exactly is your reproducibility project providing in terms of scientific and technical validation.°

2\) The two repeated experiments analyze the source of POSTN expression in the lung and whether it affects the number/size of primary and secondary tumor formation in a spontaneous mouse model of breast cancer (MMTV-PyMT). Please provide justification for these particular choices of experiments. The reviewers suggest starting the manuscript by an overview of the original results and experimental designs, and the reasoning for repeating the two selected experiments. This would help the reader, who may not be familiar with the original work, to better evaluate the scope and focus of this repetition.°

3\) Discussing the results of the original study, reproduced here, in the context of other work published over the last few years, would also be very helpful.°

4\) Finally, the use of statistics requires some explanation. For protocol 1, the authors should discuss their treatment of outliers: why such outliers have arisen and how they can be best handled in the analysis. For protocol 2, very small numbers in each group are planned and this is due to assuming the data is normally distributed. The normality of data should be addressed in the analysis and if data is not clearly normally distributed it would be fair to relax the normality assumption and check that conclusions are not changed if a non-parametric comparison is used.°

10.7554/eLife.06938.003

Author response

*1) The key finding that periostin acts as a fundamental stromal factor for metastatic progression has been meanwhile experimentally validated in several independent labs by using other models. In light of this, it would be helpful to explain in more detail what exactly is your reproducibility project providing in terms of scientific and technical validation*.*°*

This project aims to evaluate the predictors of directly reproducing a subset of the published literature. Thus, the focus is on a collection of experimental outcomes, and the factors associated with them, and not the conclusions from any given paper, which are based on multiple experiments and models.

Additionally, the project is focused on direct replications (same methodology/system) compared to conceptual replications (similar experiment, but different techniques/models). Conceptual replication is as vital for gaining understanding of an effect as direct replication is for increasing confidence that the effect occurs. The focus on understanding if the effects drawn from a single model can be reproduced will provide a means to understand the challenges and predictors of reproducing any given experiment based on current research and reporting practices. While this does not speak to the robustness of the effect, such as can be inferred through multiple models/approaches, it does provide a mechanism to examine the extent to which an effect with a given model can be observed again. We will also limit the conclusions that can be drawn to only this model.

*2) The two repeated experiments analyze the source of POSTN expression in the lung and whether it affects the number/size of primary and secondary tumor formation in a spontaneous mouse model of breast cancer (MMTV-PyMT). Please provide justification for these particular choices of experiments. The reviewers suggest starting the manuscript by an overview of the original results and experimental designs, and the reasoning for repeating the two selected experiments. This would help the reader, who may not be familiar with the original work, to better evaluate the scope and focus of this repetition*.*°*

Thank you for the suggestion. We have included an additional paragraph to describe the original work and the rational for the two selected experiments included.

*3) Discussing the results of the original study, reproduced here, in the context of other work published over the last few years, would also be very helpful*.*°*

We have expanded the Introduction to include other published studies in the context of the original study.

*4) Finally, the use of statistics requires some explanation. For protocol 1, the authors should discuss their treatment of outliers: why such outliers have arisen and how they can be best handled in the analysis. For protocol 2, very small numbers in each group are planned and this is due to assuming the data is normally distributed. The normality of data should be addressed in the analysis and if data is not clearly normally distributed it would be fair to relax the normality assumption and check that conclusions are not changed if a non-parametric comparison is used*.*°*

For protocol 1, we've included language to discuss the detection of outliers and plan to perform the test with and without the outliers to ascertain if a difference occurs in the analysis. The original analysis appears to have excluded the outliers in the statistical test they used. Additionally, we have further explored the original estimated data and the metastatic foci counts violate the normality and homoscedasticity assumption of the test used, as determined by the Shapiro--Wilk test (and Q--Q plots) and Levene's test. So, in addition to a Student's *t*-test (which was originally performed) we plan to analyze the data using negative binomial regression. The power calculations were also performed again to ensure the sample size was still adequate for this test.

For protocol 2, we have added language to the manuscript to clarify that we will perform tests for normality and homoscedasticity.

[^1]: This excludes one outlier data point (2.83) from the *Postn*^*−/−*^ data.

[^2]: This excludes one outlier data point (61) from the *Postn*^*+/+*^ data and two outlier data points (18 and 13) from the *Postn*^*−/−*^ data.

[^3]: The original data were randomly sampled from, with replacement, to create simulated data sets. For a given *n* (the number of observations) 10,000 simulations were run and the Chi-square goodness of fit test and regression coefficient (Genotype (*Postn*^*−/−*^)) was calculated for each simulated data set. Any model fit with p \< 0.05 was excluded. The power was then calculated by counting the number of times p ≤ 0.05 and dividing by the number of model fits.

[^4]: A total sample size of 18 will be used based on the planned comparison calculations making the power 99.9%.

[^5]: 6 tumors will be used per group based on the CD31^+^ to CD45^+^ comparison making the power 99.9%.
